姑息放疗中处方剂量在体能状态之外对骨转移预后分层的增量价值
该研究纳入2013年1月至2024年10月接受骨转移姑息放疗的423例患者,评估体能状态(PS)与处方剂量对总生存(OS)的联合预后价值。多因素分析显示两者均为独立预测因子,将处方剂量加入PS可显著提高1个月至2年OS预测准确性,但3年时未达统计学显著。
要点
- PS与处方剂量均为骨转移姑息放疗患者OS的独立预测因子。
- PS联合处方剂量可改善各随访时点OS风险分层。
- 联合模型对1个月至2年OS预测有显著增量价值,3年未显著。
核心结论
- 联合PS与处方剂量可对骨转移姑息放疗患者实现更精细的短期和长期OS风险分层,且不受原发肿瘤风险分类或远处转移数目影响。
研究设计与样本
- 回顾性纳入2013年1月至2024年10月接受骨转移姑息放疗的423例患者,主要终点为OS,在1、3、6个月及1、2、3年固定随访点评估。
主要发现
- 单因素Cox回归显示不良PS(HR 2.6,95%CI 2.2-3.1,P<.001)与较低处方剂量(BED α/β=10下<39 Gy;HR 3.9,95%CI 2.8-5.3,P<.001)均与1年OS显著相关。
- 多因素分析中两者均为更差OS的独立预测因子(均P<.001)。
- AUC比较显示,将处方剂量加入PS后,1个月和3个月OS预测准确性显著提高(均P<.001),6个月P=.002,1年P=.028,2年P=.032,3年P=.086未达显著。
- Kaplan-Meier曲线log-rank检验显示,联合PS与处方剂量改善OS风险分层(所有随访期P<.001),无论原发肿瘤风险或远处转移数目。
关键数值与推荐
- 较低处方剂量定义为BED α/β=10下<39 Gy。
- 联合PS与处方剂量在1、3、6个月及1、2年显著提高OS预测准确性,3年未显著。
临床怎么用
- 在骨转移姑息放疗决策中,可同时考虑PS与处方剂量进行预后分层,以辅助识别短期和长期OS风险不同的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although the individual prognostic value of performance status (PS) and prescribed dose for overall survival (OS) in palliative radiation therapy for bone metastases has been investigated, their combined prognostic significance has not been thoroughly explored. This study aimed to evaluate the combined prognostic value of PS and prescribed dose for OS in patients with bone metastases undergoing palliative radiation therapy. METHODS AND MATERIALS: This study included 423 patients who underwent palliative radiation therapy for bone metastases between January 2013 and October 2024. The primary endpoint was OS, evaluated at fixed follow-up points of 1, 3, and 6 months, as well as 1, 2, and 3 years. RESULTS: Univariate Cox regression analysis demonstrated that 1-year OS was significantly associated with poor PS (hazard ratio, 2.6 [95% CI, 2.2-3.1]; P < .001) and a lower prescribed dose (<39 Gy in a biologically effective dose with α/β = 10; hazard ratio, 3.9 [95% CI, 2.8-5.3]; P < .001), both of which remained independent predictors of worse OS in multivariate analysis (both P < .001). Comparison of the areas under the curves showed that adding prescribed dose to PS significantly improved the predictive accuracy of OS at 1 and 3 months (both P < .001), 6 months (P = .002), 1 year (P = .028), and 2 years (P = .032). However, the improvement was not statistically significant at 3 years (P = .086). Kaplan-Meier curve analysis with log-rank tests showed that combining PS and prescribed dose improved OS risk stratification (P < .001 for all follow-up periods), regardless of primary tumor risk or the number of distant metastases. CONCLUSIONS: Combining PS and prescribed dose enabled more refined risk stratification for predicting short- and long-term OS in patients with bone metastases undergoing palliative radiation therapy, regardless of primary tumor risk classification or the number of distant metastases. Moreover, adding prescribed dose to PS provided significant incremental predictive value for OS in this setting.
引用
- Watanabe Y, Tomoda T, Iwata A, et al. Incremental Value of Radiation Dose for Prognostic Stratification Beyond Performance Status in Palliative Radiation Therapy for Bone Metastases. Adv Radiat Oncol. 2026. PMID: 42871926. doi:10.1016/j.adro.2026.102170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。